The MG-ADL Scale as a Clinical Tool: The Power of Patient Perspective

argenx Neurology

S. Muppidi

Considerations for Treatment of Adult Patients with Anti-AChR Antibo…

argenx Neurology

J. Durrani

Understanding Individualized Dosing of Two Treatments for Adult Pati…

argenx Neurology

N. J. Silvestri

Overview of Neuromuscular Disorders

ZINCARE

S. Zimba

Overview of Rozanolixizumab

Constantine Farmakidis

Myasthenia Gravis: Treatment Update

NYU Langone

J. M. Bhatt

Antibodies in Myasthenia Gravis: How to Interpret It

Ghazala Hayat

Measuring Overall Severity of Myasthenia Gravis: Evidence for the Ad…

Henry J. Kaminski

Ocular Myasthenia Gravis: A Current Overview

Raed Behbehani

Neuromuscular Disorders and Spinal Cord Injury in the ICU: Diagnosis…

Diana Greene-Chandos

Advances in Treatments for Myasthenia Gravis

Houston Methodist

E. Greene

EAN 2024 Insights: Current Updates in Myasthenia Gravis

Alessio Sarnataro

2023 Overview of Myasthenia Gravis

Houston Methodist

B. Liao

Respiratory Considerations in Neuromuscular Disease

Ileana Howard

Respiratory Issues in Myasthenic Disease and Management

Houston Methodist

M. Cao

Treatment Approach in Patients With Myasthenia Gravis

Alexis A. Lizarraga

Mycophenolate and Methotrexate Are Better Tolerated Than Azathioprin…

Katherine C. Dodd

Emerging Therapies for Neuromuscular Diseases in 2021: ALS, Dystroph…

Houston Methodist

E. Greene

Myasthenia Gravis and Other Neuromuscular Junction Disorders

Swedish

C. Edmundson

Individualized MG Treatment Based on Disease Pathogenesis

Nils Erik Gilhus